To review the biology and the pathophysiology of uterine myomas, focus on options for management, and emphasize principles that will render the decision-making process as logical as possible.
Uterine leiomyomata are among the most frequent entities encountered in the practice of gynecology. The management of patients with myomas has changed substantially during the last century and probably will continue to do so with the passage of time. The scope of this article is to review the biology and pathophysiology of myomas, focus on options for management, and emphasize principles that will render the decision-making process as logical as possible. In so doing, new information and approaches will be emphasized, with the full realization that, during the careers of many of us, management of myomas will continue to change. The purpose of this article is to present the authors' recommended approach in the diagnosis and treatment of patients with myomas, as developed from a combination of published evidence and individual clinical experience. For this purpose a MEDLINE search was conducted using a combination of keywords, such as "myoma," "leiomyoma," "fibroids," "myomectomy," and "hysterectomy." Randomized controlled studies were used when available; otherwise literature that was the most relevant to the topic was used at the authors' discretion.
Uterine leiomyomata are referred to interchangeably as myomas, fibroids, fibromyomas, leiomyofibromas, and fibroleiomyomas. Because the tumor consists of uterine smooth muscle tissue as well as fibrous tissue, the term fibroid does not adequately capture the nature of the lesion. For the sake of simplicity, this report will use the term myoma.
The importance of this disorder can easily be appreciated from the following statistics: Myomas are the most common solid pelvic tumors in women, occurring in 20 -40% of women during their reproductive years. Approximately 600,000 hysterectomies are performed per year in the United States. A diagnosis of uterine myoma is the most common indication for hysterectomy. Many surgical procedures other than hysterectomy are also commonly performed because of myomas.
Uterine myomas are benign tumors that originate from smooth muscle cells of the uterus, although in some cases the smooth muscle of uterine blood vessels may be their source. Myomas range in size from seedlings to large uterine tumors. They may be solitary or multiple and can be found within the myometrium (intramural), externally extending to the serosa (subserous), or internally impinging on the uterine cavity (submucous). Myomas may also be pedunculated and extend through the internal os of the cervix. [1] [2] [3] [4] [5] Myomas are estrogen-dependent tumors. Their growth is clearly associated with exposure to circulating estrogen. Myomas predictably decrease in size during menopause and under other hypoestrogenic conditions. They exhibit maximum growth during a woman's reproductive life when estrogen secretion is maximal, demonstrating a spurt in growth in the decade before menopause. This growth spurt may be a function of anovulatory cycles with unopposed circulating estrogen. Myomas occasionally grow during pregnancy, 6 a phenomenon that may be caused by estrogens, but also by increased blood flow and edema. Estrogen receptors are present in higher concentration in uterine myomas than in adjacent myometrium. They bind 20% more estradiol (E2) per milligram of cytoplasmic protein than normal adjacent myometrium. 7 Growth patterns and locations within the uterus appear to be the major determinants of the clinical manifestations of myomas.
CLINICAL MANIFESTATIONS
Most patients with uterine myomas are symptom-free. 5, 8 When symptoms occur, they usually correlate with the location of the myomas, their size, or concomitant degenerative changes. 9, 10 Excessive menstrual bleeding, attributed to vascular alterations of the endometrium, is often the only symptom produced by myomas. The obstructive effect on uterine vasculature produced by intramural tumors leads to endometrial venule ectasia. 11, 12 As a consequence, proximal congestion in the myometrium and endometrium occurs, and this contributes to excessive bleeding during cyclic sloughing of the endometrium. The increased size of the uterine cavity and the surface area of the endometrium also contribute to increasing the quantity of menstrual flow. 13 Hypermenorrhea may be further aggravated by the presence of endometritis, which is frequently observed histologically in the endometrial tissue overlying submucous tumors. 14 A dysregulation of local growth factors and aberrant angiogenesis has also been implicated in the abnormal bleeding patterns observed in women with myomas. 15 Pain, as a symptom of myomas, is relatively infrequent. It is usually associated with torsion of the pedicle of a pedunculated myoma, cervical dilatation by a submucous myoma protruding through the lower uterine segment, or carneous degeneration associated with pregnancy. In each of these 3 conditions, pain is acute and requires immediate attention. Adenomyosis is frequently found in patients with myomas, and diffuse adenomyosis may be the cause of pain. This condition can be difficult to diagnose, especially in a uterus distorted by myomas, but magnetic resonance imaging (MRI) may prove helpful in detecting adenomyosis and differentiating it from myomas. Other pathologic conditions, including ectopic pregnancy, rupture or torsion of an ovarian cyst, or acute pelvic inflammatory disease, need to be considered in any woman with identifiable myomas who experiences acute abdominal pain. It is a mistake to automatically attribute pain experienced in association with myoma to the myoma itself.
Pressure and increased abdominal girth are more commonly encountered than pain. These symptoms develop insidiously, are often less apparent, and are usually vaguely described. As myomas grow, pressure is exerted on adjacent viscera with manifestations from the urinary tract, such as frequency, outflow obstruction, and compression of the ureter(s). 16 Gastrointestinal symptoms such as constipation or tenesmus may be the result of a posterior wall myoma that is exerting pressure on the recto-sigmoid. Rectal pressure is rare unless the myomatous uterus is incarcerated in the cul-de-sac or contains a solitary large posterior wall myoma.
Infertility is rarely caused by myomas, but when it is, it is associated with a submucous myoma 17, 18 or a markedly distorted, enlarged endometrial cavity that interferes with normal implantation or with sperm transportation. 19 Severe displacement of the cervix is also capable of adversely affecting sperm deposition at the cervical os. Likewise, intramural myomas may cause obstruction or dysfunction of the tubal ostia or intramural portion of the tubes. For patients undergoing in vitro fertilization, distortion of the endometrial cavity by myomas is associated with decreased pregnancy rates and spontaneous abortion rates in up to 50% of cases. 20 Uterine myomas have also been implicated in recurrent pregnancy loss. 21, 22 Although there are no prospective studies to compare expectant management with myomectomy in otherwise asymptomatic women, most authors agree that there is an improvement in reproductive outcome after surgery. [23] [24] [25] Malignant transformation of myomas is extremely rare. It is felt that leiomyosarcomas arise de novo and may be unrelated to benign leiomyomata. 1 In a report of presumed myomas examined in the pathology laboratory at The Johns Hopkins Hospital in 1965, 0.29% were malignant, 2 whereas, according to Corscaden and Singh, 3 malignancy occurred in less than 0.13%. Even this figure appears high, considering that most myomas are never removed, and not all those that are removed undergo section and histologic study. More recently, in a series of 1,332 women who underwent hysterectomy or myomectomy for symptomatic myomas, 4 uterine sarcoma (leiomyosarcoma, endometrial stromal sarcoma, and mixed mesodermal tumor) was found in 0.23%. Taking into account that only a small percentage of women with uterine myomas are symptomatic and may require surgery, a more realistic figure for malignancy with presumed uterine myomas is probably much smaller than the rates cited above.
GROWTH PATTERNS
Because malignancy in association with myomas is rare, careful consideration must be given to specific indications for performing surgery. A history of rapid growth, for example, an increase in uterine size by 6 weeks in a year, 5 especially postmenopausal growth, should prompt resection of the tumor(s), even in the absence of associated symptoms. Rapid growth of myomas is common during pregnancy. 26 Therefore, in younger patients in whom pregnancy has been ruled out and in older patients beyond menopause, rapid growth must raise the suspicion of a malignancy. Nevertheless, the risk of malignancy even with rapidly enlarging myomas remains very low, as mentioned above. 4 Small asymptomatic myomas require only serial follow-up, initially at 3-month intervals to establish a growth pattern. If the growth pattern is stationary, pelvic examinations can be safely repeated at 4-to 6-month intervals. Myomas often remain constant in size for many years. Because uterine size tends to vary with phase of the menstrual cycle and tissue response to hormonal stimulation, selection of a uniform time in the cycle for each follow-up examination is desirable. Myomas tend to exhibit precipitous growth during the fifth decade of a woman's life. With larger asymptomatic tumors, expectant management may be justified, provided the examiner is confident that the pelvic mass consists exclusively of myomas and does not either represent an ovarian neoplasm or obscure the detection of such an extrauterine tumor. The expectant approach is clearly applicable to women approaching menopause.
Ultrasound examination also assists in documenting growth of myomas with a finer level of discrimination than that obtained by serial pelvic examination. The presence of hydronephrosis can also be determined.
Intravenous pyelography may be occasionally necessary to define renal and ureteral characteristics when ureteral distortion is strongly suspected. In specific cases, computed tomography can supplement ultrasonography. However, it has been reported that 5% of patients diagnosed with myomas by computed tomography were subsequently found to have an ovarian tumor at the time of surgery. 27 Magnetic resonance imaging provides better discrimination of the source of a pelvic mass. 28 Regardless of imaging procedures, in the event of diagnostic uncertainty, surgical exploration may be required.
Hysterosalpingography (HSG) is especially effective in evaluating the contour of the endometrial cavity and the patency of the fallopian tubes in infertility patients who have uterine myomas (Fig. 1 ) and in women before having in vitro fertilization. Hysterosalpingography or sonohysterography may further assist in delineating the location, extent, and resectability of submucous myomas when planning the route of surgery in noninfertile women. Occasionally peritoneal distribution of the contrast media may outline the silhouette of a large pedunculated tumor (Fig. 2) .
Careful observation is suitable management for most myomas. 29 Most myomas produce no symptoms, are confined to the pelvis, and are rarely malignant. Clinical settings that may require aggressive management of uterine myomas are shown in the Box. 
Indications for Surgical Management of Uterine Myomas

THERAPY
Management of uterine myomas may involve one of the following approaches or a combination thereof: expectant management, medical management (GnRH analogues, progestational compounds, antiprogestins), surgical management (myomectomy or hysterectomy), uterine artery embolization, and other approaches, eg, high frequency ultrasonography, laser treatment, cryotherapy, or thermoablation. The choice of approach should be predicated upon careful consideration of many factors, both medical and social, including age, parity, childbearing aspirations, extent and severity of symptoms, size and number of myomas, location of myomas, associated medical condition(s), possibility of malignancy, proximity to menopause, and desire for uterine preservation. For example, a woman with multiple myomas who has completed her childbearing may benefit from hysterectomy, whereas myomectomy is appropriate for a nulliparous woman. A patient with submucosal myomas may benefit from hysteroscopic resection, whereas a patient with subserosal pedunculated symptomatic myomas may benefit from laparoscopic resection.
There was a time when hysterectomy was the standard of care in the management of uterine myomas, whereas myomectomy was rarely invoked as the appropriate treatment. Expectancy and hormonal treatment were infrequently used. The introduction of ultrasonography, hysteroscopy, and laparoscopy, computed tomography (CT) scan, and MRI and the development of GnRH analogues have significantly altered our therapeutic approach to uterine myomas and are responsible for providing a variety of means for their management. The availability of diverse modes for managing uterine myomas, therefore, currently enables the gynecologist to individualize management by understanding each patient's specific problems, needs, and goals and then to apply sound principles based upon significant clinical experience. No 2 patients are identical. A multitude of factors must be considered before arriving at the best course of management in any given individual.
HYSTERECTOMY
Hysterectomy is the second most frequent major surgical procedure performed in women in the United States, second only to cesarean delivery. Twenty percent of women will have had a hysterectomy by the age of 40, and one third by age 65. Indications for hysterectomy include uterine myomas (33.5%), endometriosis (18.2%), uterine prolapse (16.2%), and cancer (11.2%).
Removal of the uterus has been the usual procedure of choice whenever surgery is indicated for uterine myomas and when childbearing considerations have been fulfilled. Specific exceptions include a solitary subserous or pedunculated myoma and a submucous myoma readily accessible for hysteroscopic removal. Hysterectomy is also the procedure of choice whenever there is a reasonable likelihood of malignancy within a myoma, eg, as evidenced by suspicious features on MRI or CT scan or when a myomectomy is not technically feasible, such as in patients with extensive leiomyomatosis. Although this situation occurs infrequently, myomectomy in such patients may be difficult, time-consuming, and associated with a substantial complication rate. Therefore, to balance the risks of performing a difficult and potentially complicated myomectomy, sufficient indication for uterine preservation should be evident. These issues will be revisited during the discussion of myomectomy. 30 Why do a hysterectomy? Many patients inquire, quite logically, that if their problem is exclusively the presence of leiomyomata, why remove the entire uterus? This logical question, however, fails to take into consideration whether the myomatous uterus will be morphologically normal and capable of normal function following an extensive myomectomy. Several factors should influence the gynecologist's judgment, including the age of the woman with leiomyomata and her childbearing aspirations. If she is approaching menopause and is no longer interested in pregnancy, the decision is less difficult than when the woman with multiple myomas is in her third or
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Wallach and Vlahos Uterine Myomas OBSTETRICS & GYNECOLOGY fourth decade and/or wishes to be able to conceive. The patient's comfort level regarding hysterectomy represents a major consideration. For many women, hysterectomy conjures up the specter of loss of sexuality and femininity. Before surgery, counseling and discussion with other women who have undergone hysterectomy can be very constructive. Several recent publications report improvement in quality of life for most women who have had hysterectomy and conclude that hysterectomy does not adversely influence sexuality. 31 Weber et al 32 in a prospective study also reported a high rate of satisfaction among women after abdominal hysterectomy for benign gynecologic conditions. Benefits include relief from abnormal bleeding and menstrual pain. In Weber's study, sexual function was not adversely affected by hysterectomy. The data in this study also provide evidence that the cervix and uterus are not required for coital orgasm. Two thirds of the women in the study experienced relief from urinary stress incontinence. In a prospective study 33 of 1,299 women who underwent hysterectomy for symptomatic myomas, follow-up at 3, 6, 12, 18, and 24 months thereafter showed significant improvements in symptom severity, depression and anxiety levels, and overall quality of life. Along these lines, an additional report 34 suggests that standardized measurement of quality of life among women with conditions leading to hysterectomy could help in establishing treatment guidelines. In this study, 61% of the hysterectomies performed in 482 women were done for uterine myomas. 34 Surgery to relieve bleeding, pain, pelvic pressure, and urinary tract symptoms may lead to improvement in sexual satisfaction and quality of life. Other factors that may prompt hysterectomy for uterine myomas include associated conditions, such as pelvic floor relaxation, abnormal endometrial or cervical cytology, or inability to tolerate hormonal treatment, each of which may also be alleviated by a single curative surgical procedure. Additional benefits for menopausal women following hysterectomy for myomas include elimination of the need for progestational agents, the ability to take estrogen without experiencing bleeding, and relief from concerns about myoma growth during estrogen replacement. The need for routine gynecologic follow-up commitment after hysterectomy is also simplified, compared with the frequent visits previously required for assessment of myoma growth.
Hysterectomy for uterine myomas is not free of complications. Anatomic distortions of the uterus increase the risk of damage to adjacent structures, including the urinary tract and bowel. If hysterectomy is performed for a woman who has had previous conservative uterine surgery, the presence of adhesions may increase the technical difficulty and heighten the chance of bowel injury. Urinary tract injuries tend to occur when myomas extend into the broad ligament, compress the bladder, or extend deep into the pelvis. The incidence of ureteral injury in one extensive report was 0.4 per 1,000 with total abdominal hysterectomy, and that of vesicovaginal fistula was 1.0 per 1,000. 35 In all instances these urinary tract injuries were most common after procedures that were described as technically difficult. Even in Weber's report, 32 despite the documented high degree of satisfaction after hysterectomy, 4 of 34 women developed stress incontinence after surgery. Additional longterm problems after hysterectomy for myomas include development of vaginal vault prolapse. Conservation of the cervix has been proposed for selected patients undergoing abdominal hysterectomy because of its presumed significance in sexual function. In a recent study, 36 however, there was no difference in the frequency of sexual activity and orgasm between women who underwent supracervical and those who had total hysterectomy. Supracervical hysterectomy is also associated with a decreased risk of urinary tract injury, 35 requires less operating time, and has been hypothesized to lessen the risk of vault prolapse caused by preservation of the uterosacral and cardinal ligament complex. Even if, in the most recent prospective randomized study, 37 there was no difference in pelvic relaxation symptoms between the procedures after 2 years of follow-up, we believe that this time interval may be too limited to adequately address the question.
One might consider the inclination of the surgeon to perform bilateral oophorectomy when performing an abdominal hysterectomy equivalent to an additional risk concomitant oophorectomy at the time of vaginal hysterectomy does not seem to increase morbidity. [37] [38] [39] [40] In our experience, this is true as well after abdominal hysterectomy for myomas. The Wilcox survey 41 revealed that, in 1.7 million hysterectomies performed in the United States between 1988 to 1990, uterine myoma was the primary diagnosis for 29% of white and 61% of black women. The percentage of patients undergoing concomitant bilateral oophorectomy was 61.4% for women over 45 years of age, compared with 37% for younger women. We do not automatically remove the ovaries at the time of surgery for women less than 45 years of age unless there is underlying pathology or at the patient's request.
Hysterectomy is an acceptable choice for symptomatic myomas in patients who have significant bleeding, pain, pressure, or anemia that is refractory to therapy and for whom fertility is not an issue. We always leave the decision to our patients; nevertheless, we routinely recommend hysterectomy for these patients.
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ABDOMINAL MYOMECTOMY
Myomectomy is the preferred treatment whenever preservation of the uterus is desired. It is also the procedure of choice for a solitary pedunculated leiomyoma. Myomectomy should also be considered even if childbearing is not a factor for the women with symptomatic myomas who do not want a hysterectomy. Indications for myomectomy include interference with fertility or predisposition to repeated pregnancy loss because of the nature and/or location of the myomas. Infertility is rarely a consequence of myomas, but a causal relationship may be suspected, particularly when other factors for infertility have been excluded or adequately treated and there is significant distortion of the endometrial cavity. The location of myomas is the most significant element, because they can interfere with establishment or maintenance of pregnancy. Submucous leiomyomata are clearly implicated in infertility and recurrent pregnancy loss. 19, 42 Myomectomy, therefore, is recommended before gonadotropin stimulation required for in vitro fertilization. We also recommend myomectomy in patients with large myomas that may interfere with the accessibility of the ovaries during oocyte retrieval.
Desire for uterine retention cannot be underestimated. Technology today even enables the uterus of a woman lacking ovaries to serve as a gestational vehicle by virtue of in vitro fertilization, endometrial preparation with exogenous hormone therapy, and embryo donation. Furthermore, publicity regarding unnecessary hysterectomies has motivated women to become involved in the decision-making process regarding uterine retention in the presence of benign pathology. Wide dissemination of such attitudes may render myomectomy an even more prevalent procedure in the future than it is today.
Having arrived at a decision to perform myomectomy, the surgeon must carry out a thorough preoperative appraisal, selectively using the techniques described earlier. Hypermenorrhea and other forms of abnormal bleeding require endometrial evaluation before performing a myomectomy in a patient aged more than 35 years. In women at risk for endometrial pathology, such as those with a history of chronic anovulation or with perior postmenopausal bleeding, evaluation of the endometrium should be mandatory. This can be achieved either by an office endometrial biopsy or, if there is concern about the adequacy of the sample, by hysteroscopy and dilation and curettage. A hysteroscopic examination will establish the size, shape, and location of submucous myomas, as well as determine the feasibility of hysteroscopic resection. At the time of hysteroscopy, a thorough endometrial sampling can be performed. After hysteroscopy, definitive surgery should be deferred for 4 -6 weeks to minimize the chance of disseminated infection because of endometrial contamination.
Hematological status, especially when heavy or prolonged bleeding is present, should be appraised well in advance of surgery. The patient with a normal hemoglobin should have 1 or 2 units of her own blood, obtained 2 weeks before myomectomy and stored, while she undergoes treatment with supplemental iron. For the anemic patient, pretreatment with GnRH analogues or progestational agents combined with iron supplementation can produce an amenorrheic state during which iron stores can be replenished and anemia corrected. At the end of a hormonally induced 4-to 6-month interval of amenorrhea, the hemoglobin level should return to normal and permit preparation for autologous blood collection. Even with stored autologous blood, typing and cross matching additional units of blood prepares for the possibility of significant intraoperative blood loss. Several approaches have been used to reduce blood loss, including pharmacologic vasoconstricting agents and mechanical vascular occlusion with similar success. 43 Blood loss correlates with preoperative uterine size, total weight of the myomas removed, and operating time. The general principles for abdominal myomectomy involve adequate exposure, hemostasis, careful handling of reproductive tissues, and adhesion prevention. No discussion of myomectomy is complete without paying tribute to William Alexander, 44 who described the first multiple myomectomy, Victor Bonney, 45 who felt that myomectomy is a preferable procedure, and I. C. Rubin, 46 who championed the procedure of multiple myomectomy. The technical details and surgical strategies for abdominal myomectomy are well delineated in standard gynecologic surgical textbooks.
Multiple myomectomy is frequently a more difficult and time-consuming procedure than hysterectomy. The number and location of myomas within the uterus, as well as the possibility of having had previous myomectomies and a history of recurrent myomas, also enter into the equation.
Nevertheless, not everybody agrees that abdominal myomectomy is a more morbid procedure than a hysterectomy. Several retrospective studies failed to show any difference in operative morbidity between the 2 procedures. 30, [47] [48] [49] [50] According to Iverson et al, 30 morbidity among patients undergoing abdominal myomectomy was less than that after hysterectomy. In their series they reported a decreased estimated blood loss and febrile morbidity in patients undergoing abdominal myomectomy compared with those undergoing abdominal hysterectomy for myomas. Patients in the hysterectomy group experienced ureteral, bladder, and bowel injuries,
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Wallach and Vlahos Uterine Myomas OBSTETRICS & GYNECOLOGY whereas no intraoperative visceral injuries were encountered in the myomectomy group. When reviewing these reports, one should consider that selection bias may have governed the choice of procedure. The decision to perform hysterectomy is often predicated upon the anticipated difficulty associated with myomectomy. Therefore women with large, multiple myomas, as well as those with previous multiple myomectomies, may have been preferably advised to have hysterectomy. A well-designed prospective randomized study is necessary to provide a definite answer to this question. In our experience, significant blood loss, a greater need for blood replacement, a higher frequency of postoperative anemia, paralytic ileus, and pain, as well as a longer hospital stay, frequently accompany multiple myomectomies. Long-term complications must also be considered. The need for future uterine surgery to manage recurrence of myomas is high. Following abdominal myomectomy, clinically significant recurrence rates have been reported in the range of 10% after 5 years of follow-up and one third of those patients will have a hysterectomy. 51 According to another study from the University of Milan, the 10-year recurrence rate in 622 women who had undergone myomectomy was 27%, with a steady increase in frequency throughout the course of follow-up. Age was not a factor nor was the location of the myomas, but women with a solitary myoma experienced a slightly lower recurrence rate. 52 Compared with women who had a single myoma removed, the relative risk of recurrence was 1.2 in those with 2 or 3 myomas and 2.1 with removal of 4 myomas. 53 The risk for recurrence following laparoscopic myomectomy is higher, 54 reaching up to 50% after 5 years in some reports. 55 Cervical myomas can be surgically removed with a vaginal approach in certain instances. The myoma can be removed through an already dilated cervix by advancing the bladder and making an anterior midline cervical incision. The myoma may be enucleated and the cervical incision repaired with interrupted sutures. The overlying vaginal epithelium may then be reapproximated. Preoperative and perioperative antibiotic therapy is recommended in this approach because of the hazards of ascending infection from the vagina.
When extensive dissection of the myometrium has been necessary during myomectomy, cesarean delivery is usually advisable following establishment of pregnancy. This rule of thumb should supersede the classic dogma that cesarean delivery is indicated whenever the endometrial cavity has been entered. When advising patients who desire pregnancy, the possibility of pelvic adhesions or the anatomic impairment of the interstitial portion of the oviduct as a result of dissection in this location after myomectomy should be discussed as an additional cause of postoperative infertility.
HYSTEROSCOPIC MYOMECTOMY
Hysteroscopy has been used for resection of submucosal myomas with very good results (Fig. 3) . Indications for hysteroscopic myomectomy include abnormal bleeding, history of pregnancy loss, infertility, and pain. Contraindications include endometrial cancer, lower reproductive tract infection, inability to distend the uterine cavity, inability to circumnavigate the lesion, and extension of the tumor deep into the myometrium. Long-term follow-up studies have documented that approximately 20% of subjects will require additional treatment within 5 to 10 years after initial resection, a figure that approximates that following abdominal myomectomy. Recurrences may be explained by incomplete removal of myoma tissue or by new myoma growth.
The European Society of Hysteroscopy classifies submucous myomas according to level of myometrial penetration. Category T:O includes all pedunculated submucous myomas. Submucous myomas extending less than 50% into the myometrium are classified as T:I, while those with greater than 50% penetration are classified as T:II. 56 Mapping the myomas enables the hysteroscopist to plan the surgical approach. Category T:O and T:I myomas can be performed hysteroscopically by a surgeon with modest previous experience. Category T:II myomas should usually be resected abdominally, and hysteroscopic resection should be reserved for highly skilled hysteroscopic surgeons. 
LAPAROSCOPIC MYOMECTOMY
Laparoscopic myomectomy can be performed when myomas are easily accessible, as in superficial subserous or pedunculated myomas (Fig. 4) . These myomas can be morcellated and removed through the laparoscopic cannula or placed in the cul-de-sac and removed via a colpotomy incision. A morcellating instrument has been developed which readily fragments segments of the myoma and grasps it for removal through the cannula (Fig.  5) . Laparoscopic coagulation of a myoma, or myolysis, was first performed in the late 1980s in Europe. [57] [58] [59] The procedure of myolysis was viewed as a conservative alternative to myomectomy in women wishing to preserve fertility. The procedure has been carried out with the energy of a neodymium:yttrium-aluminum-garnet (Nd:YAG) laser via denaturation of protein and destruction of vascularity. Bipolar coagulation and cryomyolysis have also been described, but sufficient follow-up has not been available to enable adequate evaluation of safety and the impact on future fertility. Cowan et al 60 reported on the outcome of 9 women who underwent cryomyolysis under MRI guidance. A mean leiomyoma volume reduction of 65% was documented in 8 patients who were available for follow-up; however, 1 patient required laparotomy and myomectomy because of the laceration of a vessel, and another had a peroneal nerve defect associated with foot drop that resolved 4 months later. 60 Uterine rupture during pregnancy following laparoscopic resection of leiomyomata has been reported and has been attributed to inadequate reconstruction of the myometrium. Nevertheless, it is still unclear whether the actual incidence of uterine rupture is higher than that following abdominal myomectomy. Laparoscopic assisted myomectomy involves laparoscopic dissection of the myomas from the uterine wall and their extraction through a minilaparotomy incision, thus sparing a large abdominal incision. Because these procedures have not been standardized to the same extent as abdominal myomectomy, the surgeon who undertakes them should be skilled in operative endoscopy. 
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The patient contemplating myomectomy should be aware of the risks involved in "conservative" surgery, as well as those associated with hysterectomy for myomas. She should also be advised of the possibility that hysterectomy may be required rather than the proposed myomectomy. This is a rare event, but a candid preoperative discussion is critical for maintaining mutual trust between the patient and her physician. Unusual cases of diffuse leiomyomatosis of the uterus discovered at the time of planned myomectomy occasionally preclude removal of myomas and necessitate hysterectomy (Fig. 6) . Unfortunately, preoperatively the surgeon is not invariably able to predict the feasibility of uterine conservation because of unforeseen technical factors. Most patients who wish to retain their childbearing function will select myomectomy over hysterectomy when given the option. For those who wish to conceive, a delay of 4 to 6 months before attempting pregnancy is recommended after the surgical procedure, because the myometrium is significantly disrupted during myomectomy. For infertility patients we recommend an HSG 4 months after the procedure to evaluate the anatomy of the uterine cavity and the fallopian tubes.
UTERINE ARTERY EMBOLIZATION
Uterine artery embolization for treatment of myomas was first described in 1995, although this approach had been used for many years to control pelvic hemorrhage. The principle is simple. By limiting blood supply to the myomas (infarction), their volume may be reduced. The embolization material, usually polyvinyl alcohol particles, is passed through a fluoroscopically guided transarterial catheter inserted in the common femoral artery to selectively occlude arteries supplying the myomas. The procedure is performed under conscious sedation by an interventional radiologist. Because of the shortened hospital stay, this minimally invasive procedure has become an attractive new alternative to abdominal surgery (myomectomy, hysterectomy). It has been recommended for patients with larger myomatous uteri who are symptomatic, women who do not want extirpative therapy, and individuals who may be poor candidates for major surgery. Most patients require overnight hospitalization for pain control. In a series of 80 patients with myomarelated hypermenorrhea, 90% reported complete cessation of symptoms after uterine artery embolization. 61 The procedure is not free of side effects and complications. Pain may persist and last for more than 2 weeks after the procedure. 62 Postembolization fever, severe postembolization syndrome, pyometra, failure of satisfactory regression of myomas, sepsis, hysterectomy, and even deaths have been reported following uterine artery embolization. 62 Ovarian failure has also been reported in 1-2% of patients after the embolization procedure. The effect of uterine artery embolization on future fertility is still in question; however, Ravina et al 63 recently reported a small series of 12 pregnancies in 9 women with symptomatic uterine leiomyomata who underwent uterine artery embolization. Uterine artery embolization will continue to attract women with uterine myomas because it can provide symptomatic relief. Because of the newness of this approach, several questions remain to be answered. These include questions about recurrence rate, long-term effects on fertility, and overall safety compared with conventional surgical treatment. Uterine artery embolization must be included as an option in the course of developing a management plan for symptomatic myomas, and this option should be discussed with the patient.
HORMONE THERAPY Progestins
Progestational agents alone have been reported to have a salutary influence on myoma growth. Norethindrone, medrogestone, and medroxyprogesterone acetate have been successfully used to achieve diminution in aggregate size of the myomatous uterus. 64 -66 These compounds were thought to produce a hypoestrogenic effect by inhibiting gonadotropin secretion and suppressing ovarian function. Progestational compounds may also exert a direct antiestrogenic effect at the cellular level. However, evidence that the antiprogesterone mifepristone decreases myoma size sheds doubt on this theory.
67-71
Gonadotropin-Releasing Hormone Analogues Gonadotropin-releasing hormone analogues (GnRHa) have been used successfully to achieve hypoestrogenism in various estrogen-dependent conditions, eg, endometriosis, precocious puberty, and uterine myomas. 72 This approach offers great promise as a primary means of conservative therapy for myomas or as an adjunct to myomectomy.
The effects of either progestational therapy or GnRHa treatment are transient, and within several cycles after discontinuing administration, myomas tend to return to their pretherapy size. 73 Adjunctive therapy with a 3-to 4-month course of GnRHa should reduce myoma size and render surgery easier, accompanied by less blood loss. In the study by Andreyko et al, 74 a daily dose of 800 mg of nafarelin for 6 months caused a mean decrease in uterine volume of 57% in 10 patients followed by serial MRI. Maheux et al 75 reported a mean decrease of 71% in myoma size following treatment with intranasal busere-
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Wallach and Vlahos Uterine Myomas lin in 9 patients. Schlaff et al 76 used leuprolide in a double-blind, placebo-controlled study and demonstrated 42.7% and 30.4% declines in nonmyoma and myoma volume, respectively, through serial MRI studies. This approach has special advantages in facilitating a hysteroscopic resection of a submucous myoma, because the time consumed in the hysteroscopic resection itself is largely a function of tissue volume. In our experience, the tissue plane separating the myoma from surrounding myometrium tends to be more fibrotic and adherent after GnRHa therapy; these observations, however, have not been substantiated in a comparative study. After a course of GnRHa, myomectomy is performed through a hypovascular myometrium, theoretically reducing blood loss. 77, 78 Pretreatment with GnRHa, however, not only facilitates the myomectomy itself, but also provides an amenorrheic interval before surgery during which hemoglobin levels can be restored in the hypermenorrheic anemic patient, enabling presurgical blood donation for subsequent autotransfusion. The concern that presurgical shrinkage of small myomas by GnRHa will render them undetectable at surgery and lead to early recurrence was not borne out by a randomized, double-blind study using placebo and leuprolide acetate. 79 Despite their efficacy in reducing myoma size, the use of GnRH agonists has been associated with significant short-and long-term side effects, such as postmenopausal symptoms and osteoporosis. Hormonal add-back therapy may alleviate some of these symptoms; however, it may also negate their beneficial effects on myoma size. 80 Severe pelvic pain occasionally will accompany shrinkage of myomas during treatment with a GnRH analogue. Results of clinical studies of GnRHa therapy for myomas are variable, and, at present, accurate prediction of responders to GnRHa appear to be impossible.
Long-term treatment of young patients is neither practical nor desirable because of the likelihood of bone loss as a consequence of hypoestrogenism during prolonged therapy with GnRHa. For perimenopausal women, however, in whom reduction in myoma volume may stabilize when menopause occurs, short-term GnRHa therapy may eliminate the need for surgery.
OTHER APPROACHES
Davies et al 81 reported a procedure in which myomas are removed through a posterior or anterior colpotomy, or both, depending on the position of the myomas. Each leiomyoma is delivered into the colpotomy and the tumor removed by enucleation or morcellation. The uterine incisions are closed in layers, and then the colpotomy incisions are closed. The procedure was completed vaginally in 32 (91.4%) of 35 patients. Pelvic hematomas developed in 4 patients. One colpotomy required resuturing. Although this approach may be useful in selected cases, it was associated with a prolonged hospital stay and is limited to carefully selected groups of patients with a small number of easily accessible leiomyomata.
Recently, an MRI-guided, high-frequency focused ultrasonography (HIFUS) has been reported to be capable of destroying myoma cells. [82] [83] [84] This noninvasive procedure is still experimental and cannot be recommended yet as a clinically effective modality for treating myomas.
The carbon dioxide laser has also been used as a surgical adjunct to myomectomy. During laparotomy, small myomas have been directly vaporized with the laser, and both medium and large leiomyomas were excised. 85 In this limited-case series, improved hemostasis, greater precision enabling removal of only abnormal tissue, and ability to remove myomas from previously inaccessible areas were described as definite advantages of laser vaporization. Nevertheless, wide acceptance of this technique borne out by long-term results through extended follow-up in a larger series of patients has not yet occurred.
Baggish et al 86 described treatment of submucous myomas with the Nd:YAG laser. One approach involves multiple passes with the clear fiber into the substance of the myoma. This maneuver devascularizes the myoma, thereby destroying its blood supply. Alternatively, the base may be transected with the laser and the myoma removed or left in the cavity to be expelled. Slicing the lesion plane by plane reduces the size of the myoma. Elements of the myoma can be removed with a sponge or forceps or can be left to be passed spontaneously. Concerns regarding incomplete removal of the leiomyoma and the fact that these approaches are limited to selected groups of patients resulted in the limited spread of these techniques.
CONCLUSION
A thorough understanding of the pathogenesis of uterine myomas, clinical presentation, and the available diagnostic tools are the keys to selecting which course to follow in treating any given patient with myomas. At the present, we should use all modalities at our disposal judiciously, with ample thought to the value and cost of diagnostic tests and the risk/benefit ratios of therapies in the management of uterine myomas. This report has described a broad range of current approaches to therapy. The experience and skill of any individual surgeon is paramount in selecting the form of treatment for myomas. These concluding comments represent the authors' assessment based upon their aggregate experience(s) in the care of patients with myomas. First, we feel
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Wallach and Vlahos Uterine Myomas OBSTETRICS & GYNECOLOGY that surgery for myomas is not always necessary and should be performed only for appropriate indications, such as uncontrollable pain or bleeding, progressive and significant growth, and poor reproductive performance once other potential causes have been eliminated or treated. Second, myomectomy, rather than hysterectomy, should be performed whenever preservation of childbearing function is a desired goal. The route for myomectomy (hysteroscopic, laparoscopic, or via laparotomy) should be predicated on the location of the myomas for removal, as well as on the individual surgeon's preferred approach. Continued follow-up without surgery is advisable mostly for patients approaching menopause. Our major indication for the use of GnRH analogues is the achievement of amenorrhea to facilitate correction of iron deficiency anemia before surgery. The authors have found that preoperative treatment with GnRH analogues before myomectomy renders the capsule surrounding the myoma more fibrous and the enclosed myomas more difficult to resect. We consider uterine artery embolization to be most effective for patients with large symptomatic myomas who are poor surgical candidates and at high risk for general anesthesia, as well as for those who are reluctant to undergo a major surgical procedure. Experience with uterine artery embolization is relatively brief, and it is premature to know with assurance whether the procedure is curative or temporizing. The effects of uterine artery embolization on future fertility need extensive further evaluation before this approach can be recommended for women who have childbearing aspirations. We determine our surgical approach, endoscopic or by laparotomy, based on size, number, extent, and location of myomas. Hysterectomy has its place in myoma management in its definitiveness. By the same token, hysterectomy, our usual recommendation for women at or near menopause, should never be imposed upon the woman who simply wishes to retain her uterus for no reason other than wanting uterine preservation. Fundamentally, all therapeutic measures, and especially invasive techniques, should be reserved for patients with symptomatic myomas. For asymptomatic women, serial follow-up for growth and/or development of symptoms is generally safe. Modalities such as myolysis and high frequency ultrasound ablation are still experimental and should be used primarily in centers where these procedures are commonly performed under carefully controlled research protocols. Howard Kelly led us into the 20th century describing treatment approaches for myomas as "expectant, palliative, abortive, or radical." 87 Now, at the beginning of the 21st century, the approaches are still the same; however, a century later we have sophisticated diagnostic and therapeutic approaches which allow us the flexibility to tailor our management according to the individual's needs.
